[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355132-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355132-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","smarca4-deficiency-in-glioblastoma-mitochondrial-transfer-from-mscs-and-the-clinical-dilemma-in-targeting-the-tumor-microenvironment","SMARCA4 deficiency in glioblastoma - Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment","","SMARCA4 is a chromatin regulator with established roles in multiple cancers, yet its function in glioblastoma (GBM) remains insufficiently defined. This study links SMARCA4 expression to GBM progression, emphasizing the tumor microenvironment. Single-cell RNA sequencing tracked niche shifts during disease development. SMARCA4 knockdown in mesenchymal stromal cells (MSCs) was assessed in vitro and in vivo using an immunodeficient xenograft model, with mechanisms centered on microtubule-dependent mitochondrial transfer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/smarca4-deficiency-in-glioblastoma-mitochondrial-transfer-from-mscs-and-the-clinical-dilemma-in-targeting-the-tumor-microenvironment/355132/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/smarca4-deficiency-in-glioblastoma-mitochondrial-transfer-from-mscs-and-the-clinical-dilemma-in-targeting-the-tumor-microenvironment/355132.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does SMARCA4 deficiency do in glioblastoma progression?","Question",{"text":63,"@type":64},"SMARCA4 knockdown in MSCs is reported to alter MSC/GBM behavior, accelerate in vivo GBM progression, and worsen outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were MSC changes during GBM progression analyzed?",{"text":68,"@type":64},"Single-cell RNA sequencing was used to examine dynamic niche cell proportion shifts, including mesenchymal stromal cells, across GBM progression stages.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism links SMARCA4-deficient MSCs to enhanced GBM growth?",{"text":72,"@type":64},"The study highlights microtubule-dependent mitochondrial transfer from MSCs, which increases mitochondrial metabolic capacity and changes the MSC proliferative phenotype.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355132,1790296369,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Neoplasia 73 (2026) 101288  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| SMARCA4 deficiency in glioblastoma: Mitochondrial transfer from MSCsand the clinical dilemma in targeting the tumor microenvironment |  |  | |\n| --- | --- | --- | --- |\n| Fan Yanga,1, Lin Chen a,1, Yuchen Shi b,1, Lude Wang a, Minfeng Tonga,*\u003Cbr>a Department of Neurosurgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, Zhejiang, China b Medical College, Jinhua University of vocation Technology, Jinhua 321000, Zhejiang, China |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords: SMARCA4\u003Cbr>Glioblastoma Mesenchymal stromal Cells Mitochondria transfer Tumor micro-environment |  | Introduction: SMARCA4, a pivotal transcription activator regulating chromatin structure, gene expression, and cellular energy metabolism, has well-documented roles in various cancers. However, its specific function in glioblastoma (GBM) pathogenesis remains underexplored. This study investigates the correlation between SMARCA4 expression and GBM progression, with a focus on the tumor microenvironment.\u003Cbr>Materials and methods: Single-cell RNA sequencing analyzed dynamic niche cell proportion shifts (e.g., mesenchymal stromal cells, MSCs) during GBM progression. SMARCA4 knockdown was executed in MSCs for in vitro functional evaluations, while an immunodeficient xenograft model was utilized to assess the impact of SMARCA4-deficient MSCs on in vivo GBM progression. Mechanistic studies focused on microtubule-dependent mitochondrial transfer in IDH mutant/wild-type tumors.\u003Cbr>Results: SMARCA4 was identified as a critical MSC regulator. Its knockdown altered MSC/GBM cell behavior in vitro, accelerated in vivo GBM progression, and worsened outcomes. SMARCA4-deficient MSCs enhanced GBM growth via mitochondrial transfer, altering MSC proliferative phenotype but increasing mitochondrial metabolic capacity.\u003Cbr>Discussion: Our findings highlight SMARCA4’s critical role in regulating MSC function within the GBM microenvironment. Targeting SMARCA4-mediated mitochondrial transfer in MSCs may represent a novel therapeutic strategy for GBM. |  |\n\nIntroduction  \nGlioblastoma (GBM) is a highly aggressive and the most common malignant primary brain tumor, characterized by rapid progression and poor prognosis, with a median survival of approximately 15 months [1]. Despite recent advances in therapy, including surgery, radiation, and chemotherapy, GBM remains notoriously difficult to treat. This is due in part to its heterogeneous nature, with tumors composed of diverse cellular subpopulations exhibiting varying gene expression profiles, proliferative rates, and differential resistance to therapies, which complicates treatment strategies and contributes to its therapeutic resistance [2]. Additionally, GBM cells display an ability to invade surrounding brain tissue, complicating surgical resection and leading to high rates of recurrence [1]. The inherent resistance to standard chemotherapy and radiation therapy further limits the efficacy of conventional treatments  \n[3,4].  \nOne of the key components influencing GBM progression is the tumor microenvironment, which provides a critical and dynamic support system for tumor cells. The GBM microenvironment is a complex ecosystem that includes tumor cells, immune cells, endothelial cells, and extracellular matrix (ECM) components, all of which actively interact to promote tumor growth and survival [5–8]. This environment not only supports tumorigenesis but also contributes to the development of therapeutic resistance, making it a critical target for novel therapeutic strategies.  \nSMARCA4 (also known as BRG1) is an essential component of the SWI/SNF chromatin remodeling complex, which regulates gene expression by modifying chromatin structure and enhancing the ac","cbCaifkcF5lJRKoi","https://ap.wps.com/l/cbCaifkcF5lJRKoi","pdf",11870910,14,"English","# Introduction\n## Glioblastoma aggressiveness and treatment resistance\n## Tumor microenvironment as a therapeutic target\n## SMARCA4 biology in chromatin remodeling\n# Materials and methods\n## Single-cell RNA sequencing of niche dynamics\n## SMARCA4 knockdown in MSCs\n## In vivo xenograft assessment\n## Mechanistic focus on mitochondrial transfer\n# Results\n## MSC regulation by SMARCA4\n## Effects of SMARCA4-deficient MSCs on GBM progression\n# Discussion\n## Therapeutic implications for targeting SMARCA4-mediated transfer","[{\"question\":\"What does SMARCA4 deficiency do in glioblastoma progression?\",\"answer\":\"SMARCA4 knockdown in MSCs is reported to alter MSC/GBM behavior, accelerate in vivo GBM progression, and worsen outcomes.\"},{\"question\":\"How were MSC changes during GBM progression analyzed?\",\"answer\":\"Single-cell RNA sequencing was used to examine dynamic niche cell proportion shifts, including mesenchymal stromal cells, across GBM progression stages.\"},{\"question\":\"What mechanism links SMARCA4-deficient MSCs to enhanced GBM growth?\",\"answer\":\"The study highlights microtubule-dependent mitochondrial transfer from MSCs, which increases mitochondrial metabolic capacity and changes the MSC proliferative phenotype.\"}]","SMARCA4 deficiency in glioblastoma - Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment | PDF",1790116247,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11c452d22134d9fef19a004dc226e468.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1034f1de1c7801ac6e388b36fb4f4df.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f7c00e18f8e1e6e954817da349905eb.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52f1c5106d8c8067a8d225f13097551e.webp",980,1306]